A therapeutic role for vitamin D on obesity-associated inflammation and weight-loss intervention

Inflammation Research

Volumn 64, Issue 8, 2015, Pages 565-575

  Slusher, Aaron L ^a   McAllister, Matthew J ^b   Huang, Chun Jung ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b MISSISSIPPI STATE UNIVERSITY   (United States)

^c FLORIDA ATLANTIC UNIVERSITY   (United States)

Author keywords

Cardiorespiratory fitness; Exercise; Inflammation; Obesity; Vitamin D

Indexed keywords

CALCIUM; COLECALCIFEROL; CYTOKINE; ERGOCALCIFEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; BONE METABOLISM; CALCIUM BLOOD LEVEL; CALORIC RESTRICTION; CARDIORESPIRATORY FITNESS; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; DIETARY INTAKE; EXERCISE; HEALTH SURVEY; HUMAN; IMMUNE SYSTEM; INFLAMMATION; LEUKOCYTE; MACROPHAGE; OBESITY; PRACTICE GUIDELINE; REVIEW; ULTRAVIOLET B RADIATION; VITAMIN D DEFICIENCY; WEIGHT REDUCTION; ANIMAL; DIET THERAPY; DIETARY SUPPLEMENT; DRUG EFFECTS; KINESIOTHERAPY; METABOLISM;

ANIMALS; DIETARY SUPPLEMENTS; EXERCISE THERAPY; HUMANS; INFLAMMATION; OBESITY; VITAMIN D; WEIGHT LOSS;

EID: 84937399735     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-015-0847-4     Document Type: Review

References (141)

1. MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest. 1985;76:1536–8.
2. Bischoff-Ferrari H, Borchers M, Gudat F, Dürmüller U, Stähelin H, Dick W. Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res. 2004;19:265–9.
3. McGill A-T, Stewart JM, Lithander FE, Strik CM, Poppitt SD. Relationships of low serum vitamin D3 with anthropometry and markers of the metabolic syndrome and diabetes in overweight and obesity. Nutr J. 2008;7:4.
4. Kunadian V, Ford GA, Bawamia B, Qiu W, Manson JE. Vitamin D deficiency and coronary artery disease: a review of the evidence. Am Heart J. 2014;167:283–91.
5. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81.
6. Miettinen ME, Kinnunen L, Leiviskä J, Keinänen-Kiukaanniemi S, Korpi-Hyövälti E, Niskanen L, Oksa H, Saaristo T, Tuomilehto J, Vanhala M. Association of serum 25-hydroxyvitamin D with lifestyle factors and metabolic and cardiovascular disease markers: population-based cross-sectional study (FIN-D2D). PLoS ONE. 2014;9:e100235.
7. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2007;72:690–3.
8. Khoo A-L, Chai LY, Koenen HJ, Kullberg B-J, Joosten I, van der Ven AJ, Netea MG. 1, 25-Dihydroxyvitamin D3 modulates cytokine production induced by Candida albicans: impact of seasonal variation of immune responses. J Infect Dis. 2011;203:122–30.
9. Li B, Baylink DJ, Deb C, Zannetti C, Rajaallah F, Xing W, Walter MH, Lau K-HW, Qin X. 1, 25-Dihydroxyvitamin D3 suppresses TLR8 expression and TLR8-mediated inflammatory responses in monocytes in vitro and experimental autoimmune encephalomyelitis in vivo. PLoS ONE. 2013;8:e58808.
10. Gao D, Trayhurn P, Bing C. 1, 25-Dihydroxyvitamin D3 inhibits the cytokine-induced secretion of MCP-1 and reduces monocyte recruitment by human preadipocytes. Int J Obes (Lond). 2013;37:357–65.
11. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840–6.
12. Van Gaal LF, Mertens IL, Christophe E. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875–80.
13. Braith RW, Stewart KJ. Resistance exercise training its role in the prevention of cardiovascular disease. Circulation. 2006;113:2642–50.
14. Sigal RJ, Kenny GP, Boulé NG, Wells GA, Prud’homme D, Fortier M, Reid RD, Tulloch H, Coyle D, Phillips P. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetesa randomized trial. Ann Intern Med. 2007;147:357–69.
15. Villareal DT, Chode S, Parimi N, Sinacore DR, Hilton T, Armamento-Villareal R, Napoli N, Qualls C, Shah K. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med. 2011;364:1218–29.
16. Cannell JJ, Hollis BW, Sorenson MB, Taft TN, Anderson J. Athletic performance and vitamin D. Med Sci Sports Exerc. 2009;41:1102–10.
17. Mozoåowski W. Jäccaron; drzej Sniadecki (1768–1838) on the cure of rickets. Nature. 1939;143:121.
18. IVlyton C. The geographical distribution and etiology of rickets. By Theobald A. Palm, MA, MD. The Practitioner 1890:45:270.
19. Mellanby E. The part played by an “accessory factor” in the production of experiental rickets. J Physiol. 1918–1919;52:xi–xii, liii–liv.
20. McCollum EF, Simmonds N, Becker JE, Shipley PG. Studies on experimental rickets: and experimental demonstration of the existence of a vitamin which promotes calcium deposition. J Biol Chem. 1922;53:293–312.
21. Windaus A, Linsert O, Luttringhaus A, Weidlinch G. Über das krystallisierte vitamin D2. Justus Liebigs Ann Chem. 1932;492:226–31.
22. Angus TC, Askew FA, Bourdillon RB, Bruce HM, Callow R, Fischmann C, Philpot L, Webster TA. A crystalline antirachitic substance. Proc Royal Soc Ser B. 1931;108:340–59.
23. Windaus A, Schenck F, von Werder F. Über das antirachitisch wirksame Bestrahlungsproduct aus 7-Dehydrocholesterin. HoppeSeylers Ztschr Physiol Chem. 1936;241:100–3.
24. Holick MF, MacLaughlin J, Clark M, Holick S, Potts J, Anderson R, Blank I, Parrish J, Elias P. Photosynthesis of previtamin D3 in human skin and the physiologic consequences. Science. 1980;210:203–5.
25. Tian XQ, Chen TC, Matsuoka L, Wortsman J, Holick M. Kinetic and thermodynamic studies of the conversion of previtamin D3 to vitamin D3 in human skin. J Biol Chem. 1993;268:14888–92.
26. MacLaughlin JA, Anderson R, Holick MF. Spectral character of sunlight modulates photosynthesis of previtamin D3 and its photoisomers in human skin. Science. 1982;216:1001–3.
27. Havinga E. Vitamin D, example and challenge. Experientia. 1973;29:1181–93.
28. Dubnov-Raz G, Livne N, Raz R, Cohen A, Constantini, N. Vitamin D supplementation and physical performance in adolescent swimmers. Int J Sport Nutr Exerc Metab. 2014 (Epub ahead of print).
29. Mutt SJ, Hypponen E, Saarnio J, Järvelin M-R, Herzig K-H. Vitamin D and adipose tissue-more than storage. Front Physiol. 2014;5:228.
30. Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest. 2006;116:2062–72.
31. Blunt J, DeLuca H, Schnoes H. 25-hydroxycholecalciferol. A biologically active metabolite of vitamin D3. Biochemistry. 1968;7:3317–22.
32. DeLuca H, Holick M, Schnoes H, Suda T, Cousins R. Isolation and identification of 1, 25-dihydroxycholecalciferol. A metabolite of vitamin D active in intestine. Biochemistry. 1971;10:2799–804.
33. Martini LA, Wood RJ. Vitamin D status and the metabolic syndrome. Nutr Rev. 2006;64:479–86.
34. Holick MF, MacLaughlin J, Doppelt S. Regulation of cutaneous previtamin D3 photosynthesis in man: skin pigment is not an essential regulator. Science. 1981;211:590–3.
35. Matsuoka LY, Ide L, Wortsman J, MacLaughlin JA, Holick MF. Sunscreens suppress cutaneous vitamin D3 synthesis. J Clin Endocrinol Metab. 1987;64:1165–8.
36. Clemens T, Henderson S, Adams J, Holick M. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet. 1982;319:74–6.
37. Matsuoka LY, Wortsman J, Haddad JG, Kolm P, Hollis BW. Racial pigmentation and the cutaneous synthesis of vitamin D. Arch Dermatol. 1991;127:536–8.
38. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in boston and edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab. 1988;67:373–8.
39. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr. 2004;79:362–71.
40. Tan C, Statham B, Marks R, Payne P. Skin thickness measurement by pulsed ultrasound; its reproducibility, validation and variability. Br J Dermatol. 1982;106:657–67.
41. Cheng S, Massaro JM, Fox CS, Larson MG, Keyes MJ, McCabe EL, Robins SJ, O’Donnell CJ, Hoffmann U, Jacques PF. Adiposity, cardiometabolic risk, and vitamin D status: The Framingham Heart Study. Diabetes. 2010;59:242–8.
42. Heaney RP, Holick MF. Why the iom recommendations for vitamin d are deficient. J Bone Miner Res. 2011;26:455–7.
43. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, Lieben L, Mathieu C, Demay M. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev. 2008;29:726–76.
44. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004;80:1689S–96S.
45. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol. 2009;19:73–8.
46. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–30.
47. Dong Y, Stallmann-Jorgensen IS, Pollock NK, Harris RA, Keeton D, Huang Y, Li K, Bassali R, Guo D-H, Thomas J. A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness. J Clin Endocrinol Metab. 2010;95:4584–91.
48. Aloia JF, Patel M, DiMaano R, Li-Ng M, Talwar SA, Mikhail M, Pollack S, Yeh JK. Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. Am J Clin Nutr. 2008;87:1952–8.
49. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G. The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53–8.
50. Trang HM, Cole D, Rubin LA, Pierratos A, Siu S, Vieth R. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr. 1998;68:854–8.
51. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004;89:5387–91.
52. Biancuzzo RM, Clarke N, Reitz RE, Travison TG, Holick MF. Serum concentrations of 1, 25-dihydroxyvitamin D2 and 1, 25-dihydroxyvitamin D3 in response to vitamin D2 and vitamin D3 supplementation. J Clin Endocrinol Metab. 2013;98:973–9.
53. Holick MF, Biancuzzo RM, Chen TC, Klein EK, Young A, Bibuld D, Reitz R, Salameh W, Ameri A, Tannenbaum AD. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab. 2008;93:677–81.
54. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311:806–14.
55. Konradsen S, Ag H, Lindberg F, Hexeberg S, Jorde R. Serum 1, 25-dihydroxy vitamin D is inversely associated with body mass index. Eur J Nutr. 2008;47:87–91.
56. Parikh SJ, Edelman M, Uwaifo GI, Freedman RJ, Semega-Janneh M, Reynolds J, Yanovski JA. The relationship between obesity and serum 1, 25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab. 2004;89:1196–9.
57. Pereira-Santos M, Costa PRF, Assis AMO, Santos CAST, Santos DB. Obesity and vitamin D deficiency: a systemic review and meta-analysis. Obes Rev. 2015;16:341–9.
58. Compston JE, Vedi S, Ledger JE, Webb A, Gazet J-C, Pilkington T. Vitamin D status and bone histomorphometry in gross obesity. Am J Clin Nutr. 1981;34:2359–63.
59. Kamycheva E, Joakimsen RM, Jorde R. Intakes of calcium and vitamin D predict body mass index in the population of Northern Norway. J Nutr. 2003;133:102–6.
60. Rodríguez-Rodríguez E, Navia B, López-Sobaler AM, Ortega RM. Vitamin D in overweight/obese women and its relationship with dietetic and anthropometric variables. Obesity (Silver Spring). 2009;17:778–82.
61. Liel Y, Ulmer E, Shary J, Hollis BW, Bell NH. Low circulating vitamin D in obesity. Calcif Tissue Int. 1988;43:199–201.
62. Rosenstreich SJ, Rich C, Volwiler W. Deposition in and release of vitamin D3 from body fat: evidence for a storage site in the rat. J Clin Invest. 1971;50:679–87.
63. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care. 2005;28:1228–30.
64. Mitri J, Muraru M, Pittas A. Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr. 2011;65:1005–15.
65. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D’Agostino RB, Wolf M, Vasan RS. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117:503–11.
66. Norman AW. Vitamin d receptor: new assignments for an already busy receptor. Endocrinology. 2006;147:5542–8.
67. Plum LA, DeLuca HF. Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov. 2010;9:941–55.
68. Demay MB. Mechanism of vitamin D receptor action. Ann NY Acad Sci. 2006;1068:204–13.
69. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P. The nuclear receptor superfamily: the second decade. Cell. 1995;83:835–9.
70. Blumberg JM, Tzameli I, Astapova I, Lam FS, Flier JS, Hollenberg AN. Complex role of the vitamin D receptor and its ligand in adipogenesis in 3T3-L1 cells. J Biol Chem. 2006;281:11205–13.
71. Ding C, Gao D, Wilding J, Trayhurn P, Bing C. Vitamin D signalling in adipose tissue. Br J Nutr. 2012;108:1915–23.
72. Stephens JM. The fat controller: adipocyte development. PLoS Biol. 2012;10:e1001436.
73. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280:E745–51.
74. Lehr S, Hartwig S, Lamers D, Famulla S, Müller S, Hanisch F-G, Cuvelier C, Ruige J, Eckardt K, Ouwens DM. Identification and validation of novel adipokines released from primary human adipocytes. Mol Cell Proteomics. 2012;11(M111):010504.
75. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796–808.
76. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821–30.
77. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175–84.
78. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–7.
79. Vlasova M, Purhonen A, Jarvelin M, Rodilla E, Pascual J, Herzig K. Role of adipokines in obesity-associated hypertension. Acta Physiol (Oxf). 2010;200:107–27.
80. Bland R, Markovic D, Hills CE, Hughes SV, Chan SL, Squires PE, Hewison M. Expression of 25-hydroxyvitamin D3-1α-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol. 2004;89–90:121–5.
81. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1α-hydroylase in human brain. J Chem Neuroanat. 2005;29:21–30.
82. Zehnder D, Bland R, Chana RS, Wheeler DC, Howie AJ, Williams MC, Stewart PM, Hewison M. Synthesis of 1,25-dihydroxyvitamin D3 by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol. 2002;13:621–91.
83. Somjen D, Weisman Y, Kohen F, Gayer B, Limor R, Sharon O, Jaccard N, Knoll E, Stern N. 25-hydroxyvitamin D3-1α-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation. 2005;5:1666–71.
84. Li J, Byrne ME, Chang E, Jiang Y, Donkin SS, Buhman KK, Burgess JR, Teegarden D. 1α,25-dihydroxyvitamin D hydroxylase in adipocytes. J Steroid Biochem Mol Biol. 2008;112:122–6.
85. Hewison M. Vitamin D and the immune system: new perspectives on an old theme. Endocrinol Metab Clin North Am. 2010;39:365–79.
86. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311:1770–3.
87. vinh qu[InlineMediaObject not available: see fulltext.]c L[InlineMediaObject not available: see fulltext.][InlineMediaObject not available: see fulltext.]ng K, Nguy[InlineMediaObject not available: see fulltext.]n LT. The beneficial role of vitamin D in obesity: possible genetic and cell signaling mechanisms. Nutr J. 2013;12:89.
88. Vitseva OI, Tanriverdi K, Tchkonia TT, Kirkland JL, McDonnell ME, Apovian CM, Freedman J, Gokce N. Inducible toll-like receptor and NF-κB regulatory pathway expression in human adipose tissue. Obesity (Silver Spring). 2008;16:932–7.
89. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 2010;11:373–84.
90. Könner AC, Brüning JC. Toll-like receptors: linking inflammation to metabolism. Trends Endocrinol Metab. 2011;22:16–23.
91. Creely SJ, McTernan PG, Kusminski CM, Da Silva N, Khanolkar M, Evans M, Harte A, Kumar S. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292:E740–7.
92. Scholtes VP, Versteeg D, de Vries J-PP, Hoefer IE, Schoneveld AH, Stella PR, Doevendans PA, van Keulen KJ, de Kleijn DP, Moll FL. Toll-like receptor 2 and 4 stimulation elicits an enhanced inflammatory response in human obese patients with atherosclerosis. Clin Sci. 2011;121:205–14.
93. Kim S-J, Choi Y, Choi Y-H, Park T. Obesity activates toll-like receptor-mediated proinflammatory signaling cascades in the adipose tissue of mice. J Nutr Biochem. 2012;23:113–22.
94. Davis JE, Braucher DR, Walker-Daniels J, Spurlock ME. Absence of TLR2 protects against high-fat diet-induced inflammation and results in greater insulin-stimulated glucose transport in cultured adipocytes. J Nutr Biochem. 2011;22:136–41.
95. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, Schenka AA, Araújo EP, Vassallo J, Curi R, Velloso LA. Loss-of-function mutation in toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes. 2007;56:1986–98.
96. Khoo AL, Chai L, Koenen H, Sweep F, Joosten I, Netea M, van der Ven A. Regulation of cytokine responses by seasonality of vitamin D status in healthy individuals. Clin Exp Immunol. 2011;164:72–9.
97. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83:754–9.
98. Petchey WG, Johnson DW, Isbel NM. Shining D’light on chronic kidney disease: mechanisms that may underpin the cardiovascular benefit of vitamin D. Nephrology (Carlton). 2011;16:351–67.
99. Bolland MJ, Grey AB, Ames RW, Mason BH, Horne AM, Gamble GD, Reid IR. The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. Am J Clin Nutr. 2007;86:959–64.
100. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for jnk in obesity and insulin resistance. Nature. 2002;420:333–6.
101. Nguyen MA, Satoh H, Favelyukis S, Babendure JL, Imamura T, Sbodio JI, Zalevsky J, Dahiyat BI, Chi N-W, Olefsky JM. JNK and tumor necrosis factor-α mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem. 2005;280:35361–71.
102. Sun H, Charles CH, Lau LF, Tonks NK. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell. 1993;75:487–93.
103. Ito A, Suganami T, Miyamoto Y, Yoshimasa Y, Takeya M, Kamei Y, Ogawa Y. Role of MAPK phosphatase-1 in the induction of monocyte chemoattractant protein-1 during the course of adipocyte hypertrophy. J Biol Chem. 2007;282:25445–52.
104. Oh J, Weng S, Felton SK, Bhandare S, Riek A, Butler B, Proctor BM, Petty M, Chen Z, Schechtman KB. 1,25(OH)2 vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation. 2009;120:687–98.
105. Lorente-Cebrián S, Eriksson A, Dunlop T, Mejhert N, Dahlman I, Aström G, Sjölin E, Wåhlén K, Carlberg C, Laurencikiene J, Hedén P, Arner P, Rydén M. Differential effects of 1α,25-dihydroxycholecalciferol on MCP-1 and adiponectin production in human white adipocytes. Eur J Nutr. 2012;51:335–42.
106. Chen Y, Zhang J, Ge X, Du J, Deb DK, Li YC. Vitamin D receptor inhibits nuclear factor κB activation by interacting with IκB kinase β protein. J Biol Chem. 2013;5:19450–8.
107. Canning MO, Grotenhuis K, de Wit H, Ruwhof C, Drexhage HA. 1-alpha,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. Eur J Endocrinol. 2001;145:351–7.
108. Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther. 2008;324:23–33.
109. Zhang X, Zhou M, Guo Y, Song Z, Liu B. 1,25-dihydroxyvitamin D3 promotes high glucose-induced M1 macrophage switching to M2 via the VDR-PPARγ signaling pathway. Biomed Res Int. 2015;2015:157834.
110. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;25:129–39.
111. Do Lee C, Blair SN, Jackson AS. Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men. Am J Clin Nutr. 1999;69:373–80.
112. Lee D-C, Sui X, Artero EG, Lee I-M, Church TS, McAuley PA, Stanford FC, Kohl HW, Blair SN. Long-term effects of changes in cardiorespiratory fitness and body mass index on all-cause and cardiovascular disease mortality in men the aerobics center longitudinal study. Circulation. 2011;124:2483–90.
113. Kullo IJ, Khaleghi M, Hensrud DD. Markers of inflammation are inversely associated with VO2 max in asymptomatic men. J Appl Physiol. 1985;2007(102):1374–9.
114. Mowry DA, Costello MM, Heelan KA. Association among cardiorespiratory fitness, body fat, and bone marker measurements in healthy young females. J Am Osteopath Assoc. 2009;109:534–9.
115. Christiansen T, Paulsen SK, Bruun JM, Pedersen SB, Richelsen B. Exercise training versus diet-induced weight-loss on metabolic risk factors and inflammatory markers in obese subjects: a 12-week randomized intervention study. Am J Physiol Endocrinol Metab. 2010;298:E824–31.
116. Steensberg A, Toft AD, Bruunsgaard H, Sandmand M, Halkjær-Kristensen J, Pedersen BK. Strenuous exercise decreases the percentage of type 1 T cells in the circulation. J Appl Physiol. 1985;2001(91):1708–12.
117. Steensberg A, Toft AD, Schjerling P, Halkjær-Kristensen J, Pedersen BK. Plasma interleukin-6 during strenuous exercise: role of epinephrine. Am J Physiol Cell Physiol. 2001;281:C1001–4.
118. Yamada M, Suzuki K, Kudo S, Totsuka M, Nakaji S, Sugawara K. Raised plasma G-CSF and IL-6 after exercise may play a role in neutrophil mobilization into the circulation. J Appl Physiol. 1985;2002(92):1789–94.
119. Smith L, Anwar A, Fragen M, Rananto C, Johnson R, Holbert D. Cytokines and cell adhesion molecules associated with high-intensity eccentric exercise. Eur J Appl Physiol. 2000;82:61–7.
120. MacIntyre DL, Sorichter S, Mair J, Berg A, McKenzie DC. Markers of inflammation and myofibrillar proteins following eccentric exercise in humans. Eur J Appl Physiol. 2001;84:180–6.
121. Peake J, Nosaka KK, Muthalib M, Suzuki K. Systemic inflammatory responses to maximal versus submaximal lengthening contractions of the elbow flexors. Exerc Immunol Rev. 2006;12:72–85.
122. Gokhale R, Chandrashekara S, Vasanthakumar K. Cytokine response to strenuous exercise in athletes and non-athletes—an adaptive response. Cytokine. 2007;40:123–7.
123. Fischer CP, Plomgaard P, Hansen AK, Pilegaard H, Saltin B, Pedersen BK. Endurance training reduces the contraction-induced interleukin-6 mRNA expression in human skeletal muscle. Am J Physiol Endocrinol Metab. 2004;287:E1189–94.
124. Harris RA, Padilla J, Hanlon KP, Rink LD, Wallace JP. The flow-mediated dilation response to acute exercise in overweight active and inactive men. Obesity (Silver Spring). 2008;16:578–84.
125. Christiansen T, Bruun JM, Paulsen SK, Ølholm J, Overgaard K, Pedersen SB, Richelsen B. Acute exercise increases circulating inflammatory markers in overweight and obese compared with lean subjects. Eur J Appl Physiol. 2013;113:1635–42.
126. Ploeger HE, Takken T, De Greef M, Timmons BW. The effects of acute and chronic exercise on inflammatory markers in children and adults with a chronic inflammatory disease: a systematic review. Exerc Immunol Rev. 2009;15:6–41.
127. Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am J Physiol Endocrinol Metab. 2005;290:E961–7.
128. Bruunsgaard H. Physical activity and modulation of systemic low-level inflammation. J Leukoc Biol. 2005;78:819–35.
129. Stewart LK, Flynn MG, Campbell WW, Craig BA, Robinson JP, McFarlin BK, Timmerman KL, Coen PM, Felker J, Talbert E. Influence of exercise training and age on CD14 + cell-surface expression of toll-like receptor 2 and 4. Brain Behav Immun. 2005;19:389–97.
130. Straczkowski M, Kowalska I, Dzienis-Straczkowska S, Stepien A, Skibinska E, Szelachowska M, Kinalska I. Changes in tumor necrosis factor-alpha system and insulin sensitivity during an exercise training program in obese women with normal and impaired glucose tolerance. Eur J Endocrinol. 2001;145:273–80.
131. Kawanishi N, Yano H, Yokogawa Y, Suzuki K. Exercise training inhibits inflammation in adipose tissue via both suppression of macrophage infiltration and acceleration of phenotypic switching from M1 to M2 macrophages in high-fat-diet-induced obese mice. Exerc Immunol Rev. 2010;16:105–18.
132. Phillips MD, Patrizi RM, Cheek DJ, Wooten JS, Barbee JJ, Mitchell JB. Resistance training reduces subclinical inflammation in obese, postmenopausal women. Med Sci Sports Exerc. 2012;44:2099–110.
133. Kopp H-P, Kopp C, Festa A, Krzyzanowska K, Kriwanek S, Minar E, Roka R, Schernthaner G. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol. 2003;23:1042–7.
134. Reinehr T, de Sousa G, Alexy U, Kersting M, Andler W. Vitamin D status and parathyroid hormone in obese children before and after weight loss. Eur J Endocrinol. 2007;157:225–32.
135. Tzotzas T, Papadopoulou FG, Tziomalos K, Karras S, Gastaris K, Perros P, Krassas GE. Rising serum 25-hydroxy-vitamin D levels after weight loss in obese women correlate with improvement in insulin resistance. J Clin Endocrinol Metab. 2010;95:4251–7.
136. Villareal DT, Shah K, Banks MR, Sinacore DR, Klein S. Effect of weight loss and exercise therapy on bone metabolism and mass in obese older adults: a one-year randomized controlled trial. J Clin Endocrinol Metab. 2008;93:2181–7.
137. Rosenblum JL, Castro VM, Moore CE, Kaplan LM. Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults. Am J Clin Nutr. 2012;95:101–8.
138. Zittermann A, Frisch S, Berthold HK, Götting C, Kuhn J, Kleesiek K, Stehle P, Koertke H, Koerfer R. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr. 2009;89:1321–7.
139. Major GC, Alarie F, Doré J, Phouttama S, Tremblay A. Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr. 2007;85:54–9.
140. You T, Berman DM, Ryan AS, Nicklas BJ. Effects of hypocaloric diet and exercise training on inflammation and adipocyte lipolysis in obese postmenopausal women. J Clin Endocrinol Metab. 2004;89:1739–46.
141. Rayalam S, Della-Fera MA, Ambati S, Yang JY, Park HJ, Baile CA. Enhanced effects of 1,25(OH)2D3 plus genistein on adipogenesis and apoptosis in 3T3-L1 adipocytes. Obesity (Silver Spring). 2008;16:539–46.